24310-18-7

Basic information

• Product Name: isovalerichydrazide
• Synonyms: 3-methylbutanoicacidhydrazide;3-methyl-butanoicacihydrazide;isobutylcarbonylhydrazine;isovaleriansaeurehydrazid;isovalericacid,hydrazide;isovalerichydrazide;3-methylbutanohydrazide(SALTDATA: FREE);Butanoic acid, 3-Methyl-, hydrazide
• CAS NO: 24310-18-7
• Molecular Formula: C₅H₁₂N₂O
• Molecular Weight: 116.16158
• Mol File: 24310-18-7.mol

Chemical Properties

• Melting Point: 158 °C
• Boiling Point: 250.8°C at 760 mmHg
• Flash Point: 105.5°C
• Appearance: /
• Density: 0.959g/cm³
• Vapor Pressure: 0.0212mmHg at 25°C
• Refractive Index: 1.446
• PKA: 13.59±0.18(Predicted)
• CAS DataBase Reference: isovalerichydrazide(CAS DataBase Reference)
• NIST Chemistry Reference: isovalerichydrazide(24310-18-7)
• EPA Substance Registry System: isovalerichydrazide(24310-18-7)

Safety Data

• Hazardous Substances Data: 24310-18-7(Hazardous Substances Data)

Usage

Uses

Used in Chemical Industry:
Isovalerichydrazide is used as a curing agent for epoxy resins, facilitating the hardening process and enhancing the material's properties for various applications.
Used in Rubber Industry:
In the rubber industry, isovalerichydrazide serves as a rubber accelerator, expediting the vulcanization process and improving the rubber's performance characteristics.
Used in Metalworking Fluids:
Isovalerichydrazide is utilized as a corrosion inhibitor in metalworking fluids, protecting metal surfaces from corrosion and extending the life of the equipment and tools.
Used in Plastics Industry:
As a stabilizer in plastics, isovalerichydrazide helps to prevent degradation and maintain the plastic's integrity over time, ensuring consistent quality and performance.
Used in Pharmaceutical Industry:
Isovalerichydrazide is employed as a building block in the synthesis of various drugs, contributing to the development of new pharmaceutical compounds with potential therapeutic benefits.
Safety Measures:
Due to its potential hazards if ingested, inhaled, or absorbed through the skin, isovalerichydrazide requires careful handling and proper storage to ensure safety in its applications.

InChI:InChI=1/C5H12N2O/c1-4(2)3-5(8)7-6/h4H,3,6H2,1-2H3,(H,7,8)

Upstream product

• 108-64-5 Ethyl isovalerate 
• 108-12-3 isopentanoyl chloride 
• 556-24-1 methyl 3-methylbutanoate 
• 503-74-2 3-methylbutyric acid 

Downstream Products

• 99066-16-7 3-isobutyl-5-isopropyl-1H-[1,2,4]triazole 
• 91495-02-2 4-chloro-N-(5-isobutyl-[1,3,4]oxadiazol-2-yl)-benzenesulfonamide 
• 93185-65-0 N-(5-isobutyl-[1,3,4]oxadiazol-2-yl)-benzenesulfonamide 
• 93475-65-1 N-(5-isobutyl-[1,3,4]oxadiazol-2-yl)-toluene-4-sulfonamide 
• 34243-17-9 N-(5-isobutyl-[1,3,4]oxadiazol-2-yl)-4-methoxy-benzenesulfonamide 
• 743-94-2 2-(2-Isovaleryl-hydrazino)-5-nitroso-7-phenyl-tropon 
• 37934-20-6 dithiophosphoric acid S-(5-isobutyl-[1,3,4]oxadiazol-2-ylmethyl) ester O,O'-dimethyl ester 
• 37934-22-8 thiophosphoric acid O,O'-diethyl ester S-(5-isobutyl-[1,3,4]oxadiazol-2-ylmethyl) ester 
• 3914-47-4 2-chloromethyl-5-isobutyl-[1,3,4]oxadiazole 
• 1185281-11-1 N-(3-(1,7-dimethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-methylphenyl)-2-(3-methylbutanoyl)hydrazinecarboxamide 
• 1477524-43-8 5-isobutyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,3,4-oxadiazol-2-amine 

Relevant articles and documents

Fragment-based drug discovery of triazole inhibitors to block PDEδ-RAS protein-protein interaction

Although mutated Ras protein is well recognized as an important drug target, direct targeting Ras has proven to be a daunting task. Recent studies demonstrated that Ras protein needs PDEδ to relocate to plasma membrane to execute its signaling transduction function, which provides a new avenue for modulating the Ras protein. To find small molecules antagonizing the interactions between PDEδ and Ras, here we presented a successful application of fragment-based drug discovery of PDEδ inhibitors. Under the guidance of crystal structures, we are able to quickly optimize the initial fragment into highly potent inhibitors, with more than 2000-fold improvement in binding activity, which further adds to the arsenal towards the inhibition of Ras signaling in cancer therapy.

Triazole derivative, preparation method and uses thereof

The present invention relates to a PDE inhibitor, particularly to a PDE[delta] inhibitor, specifically to a triazole derivative represented by a general formula (I), a preparation method and uses thereof. According to the present invention, a series of the compounds have good PDE[delta] inhibitory activities, can be used for preparing drugs for treating or preventing KRas-PDE[delta]-mediated diseases, and are particularly suitable for the preparation of KRas-PDE[delta]-mediated antitumor drugs, wherein each substituent in the general formula (I) is the same as the definition of the specification. The formula I is defined in the specification.

Combinatorial synthesis of 3,5-Dimethylene substituted 1,2,4-Triazoles

Combinatorial cyclizations of imidates and hydrazides with methylene linked R groups, generated from the corresponding nitriles and carboxylic acids, respectively, provided a large library of 3,5-dimethylene substituted 1,2,4- trizoles. 2011 Bentham Science Publishers Ltd.

INHIBITORS OF AKT ACTIVITY

The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.

Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors?

Starting from potent aldehyde inhibitors with poor drug properties, derivatization to semicarbazones led to the identification of a series of semicarbazone-based cathepsin K inhibitors with greater solubility and better pharmacokinetic profiles than their parent aldehydes. Furthermore, a representative semicarbazone inhibitor attenuated bone resorption in an ex vivo rat calvarial bone resorption model. However, based on enzyme inhibition comparisons at neutral pH, semicarbazone hydrolysis rates, and 13C NMR experiments, these semicarbazones probably function as prodrugs of aldehydes.

Indazole compounds, compositions thereof and methods of treatment therewith

This invention is generally directed to the use of Indazole Compounds for treating or preventing diseases associated with protein kinases, including tyrosine kinases, such as proliferative diseases, inflammatory diseases, abnormal angiogenesis and diseases related thereto, atherosclerosis, macular degeneration, diabetes, obesity, pain and others. The methods comprise the administration to a patient in need thereof of an effective amount of an indazole compound that inhibits, modulates or regulates tyrosine kinase signal transduction. Novel indazole compounds or pharmaceutically acceptable salt thereof are presented herein.

Methods for treating an inflammatory condition or inhibiting JNK

This invention is generally directed to Indazole Derivatives having the following structure: 1 or pharmaceutically acceptable salt thereof, wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of diseases and disorders that are responsive to JNK inhibition, such as an inflammatory disease or disorder. Thus, methods of treating such diseases and disorders are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.